Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares

Altimmune, Inc. (NASDAQ:ALT) Director Jerome Benedict Durso bought 12,500 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were acquired at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the acquisition, the director owned 12,500 shares in the company, valued at $51,625. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Altimmune Stock Up 6.2%

Shares of NASDAQ:ALT traded up $0.24 during trading hours on Monday, hitting $4.14. The company’s stock had a trading volume of 6,850,798 shares, compared to its average volume of 3,597,422. The firm’s fifty day moving average price is $4.51 and its 200 day moving average price is $4.40. Altimmune, Inc. has a 52 week low of $2.90 and a 52 week high of $8.25. The company has a market capitalization of $431.98 million, a price-to-earnings ratio of -3.87 and a beta of -0.03. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. As a group, research analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Monday, October 20th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 15th. Finally, Citizens Jmp lowered their target price on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Altimmune presently has a consensus rating of “Moderate Buy” and an average price target of $16.83.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently modified their holdings of ALT. Sherbrooke Park Advisers LLC acquired a new stake in Altimmune during the third quarter worth about $60,000. Sig Brokerage LP acquired a new position in shares of Altimmune in the 3rd quarter valued at $130,000. Millennium Management LLC grew its position in Altimmune by 7,160.7% during the third quarter. Millennium Management LLC now owns 367,582 shares of the company’s stock valued at $1,386,000 after buying an additional 372,788 shares during the period. Brevan Howard Capital Management LP raised its position in shares of Altimmune by 67.4% in the third quarter. Brevan Howard Capital Management LP now owns 222,942 shares of the company’s stock worth $840,000 after acquiring an additional 89,733 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after acquiring an additional 1,559,562 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.